Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up 144 points (+0.8%) at 17,118 as of Thursday, Oct 30, 2014, 11:36 a.m. ET. During this time, 117.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 323.9 million. The NYSE advances/declines ratio sits at 1,514 issues advancing vs. 1,420 declining with 183 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a 22-cent gain (+0.2%) bringing the stock to $105.78. This single gain is lifting the Dow Jones Industrial Average by 1.67 points or roughly accounting for 1.2% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 3.8 million shares traded vs. an average daily trading volume of 7.3 million shares.
Johnson & Johnson has a market cap of $295.54 billion and is part of the health care sector and drugs industry. Shares are up 15.3% year-to-date as of Wednesday's close. The stock's dividend yield sits at 2.7%.
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Johnson & Johnson Ratings Report.